Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib-Reference-Cited by-同舟云学术

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

Published:2009-04 Issue:2 Volume:46 Page:166-175
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Mitsiades Constantine S.,Hideshima Teru,Chauhan Dharminder,McMillin Douglas W.,Klippel Steffen,Laubach Jacob P.,Munshi Nikhil C.,Anderson Kenneth C.,Richardson Paul G.

Publisher

Elsevier BV

Subject

Hematology

Reference72 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora;Feling;Angew Chem Int Ed Engl,2003

3. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib;Chauhan;Cancer Cell,2005

4. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome;Demo;Cancer Res,2007

5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma;Kuhn;Blood,2007

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells;Archives of Medical Research;2020-04

2. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15;PLOS ONE;2019-10-22

3. AK-968 efficiently inhibits proliferation and induces cell apoptosis in human multiple myeloma cells;PHARMAZIE;2019

4. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies;Cancer Treatment Reviews;2016-02

5. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study;The Lancet Haematology;2015-12